Shhhh.....I Daytrade at work.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
added GBG - gold bug reversal coming imo
GBG-just a matter of time. Gold hit $1770 an ounce.
GBG-added some here.
TELK-this will be easy double when we get the volume IMO. Chart looks ready to reverse
check out TELK chart and news
Telik Announces Expansion of Phase 2 Trial of Telcyta in Hematologic Malignancies
Telik, Inc. (MM) (NASDAQ:TELK)
Intraday Stock Chart
Today : Tuesday 21 February 2012
Telik, Inc. (Nasdaq: TELK) today announced that the Phase 2 investigator-led Telcyta trial in hematologic malignancies has been expanded to an additional investigational site, Memorial Sloan-Kettering Cancer Center (MSKCC). Based upon the results observed in Stage 1 of the trial, which is being conducted at the Robert Wood Johnson University Hospital under the direction of Joseph R. Bertino, MD of The Cancer Institute of New Jersey, an additional 10 patients with chemotherapy resistant multiple myeloma may be enrolled. Additional trial investigators at MSKCC are Sergio A. Giralt, MD and Nikoletta Lendvai, MD, PhD.
About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.
Telik Announces Expansion of Phase 2 Trial of Telcyta in Hematologic Malignancies
Telik, Inc. (MM) (NASDAQ:TELK)
Intraday Stock Chart
Today : Tuesday 21 February 2012
Telik, Inc. (Nasdaq: TELK) today announced that the Phase 2 investigator-led Telcyta trial in hematologic malignancies has been expanded to an additional investigational site, Memorial Sloan-Kettering Cancer Center (MSKCC). Based upon the results observed in Stage 1 of the trial, which is being conducted at the Robert Wood Johnson University Hospital under the direction of Joseph R. Bertino, MD of The Cancer Institute of New Jersey, an additional 10 patients with chemotherapy resistant multiple myeloma may be enrolled. Additional trial investigators at MSKCC are Sergio A. Giralt, MD and Nikoletta Lendvai, MD, PhD.
About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.
Telik Announces Expansion of Phase 2 Trial of Telcyta in Hematologic Malignancies
Telik, Inc. (MM) (NASDAQ:TELK)
Intraday Stock Chart
Today : Tuesday 21 February 2012
Telik, Inc. (Nasdaq: TELK) today announced that the Phase 2 investigator-led Telcyta trial in hematologic malignancies has been expanded to an additional investigational site, Memorial Sloan-Kettering Cancer Center (MSKCC). Based upon the results observed in Stage 1 of the trial, which is being conducted at the Robert Wood Johnson University Hospital under the direction of Joseph R. Bertino, MD of The Cancer Institute of New Jersey, an additional 10 patients with chemotherapy resistant multiple myeloma may be enrolled. Additional trial investigators at MSKCC are Sergio A. Giralt, MD and Nikoletta Lendvai, MD, PhD.
About Telik
Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic malignancies including myelodysplastic syndrome; followed by Telcyta®, a cancer activated prodrug for the treatment of a variety of cancers. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.
Telik, the Telik logo, TELINTRA, TELCYTA and TRAP are trademarks or registered trademarks of Telik, Inc.
SOURCE Telik, Inc.
Nice bid support. Someone wants this to run...
NEWN they file to sell $20m shares
PURE finally getting slapped :)
picked some GBG on double bottom.
picked some GBG
Tell me about it. I didn't see the filing post because IHUB was down. Just now found it about the filing. Triple DOH!
Doh! now that's not good. Just added a few today too.
DHT - nice close...divy sellers gone.
IGC - working hard on breaking down that .38 resistance.
NEWN - Added a few more under .80
IGC - +18% on 187K volume. What will more buying do to it?
DHT-agreed...added a few yesterday's dip
DHT - higher lows, bouncey today
IGC - looks like it's going to break .36
DHT-IGC-NEWN
NEWN-might be good time to add under .80 imo
DHT should be support here, punched through this level end of day on Monday and hit 1.35 yesterday.
added back some DHT 1.17
IGC - nice...one MM left at .35
IGC-looks like whoever was selling is gone. stock is up 18% on 144K shares traded.
IGC looking good +18%
DHT - sellers out and now back to green
ANX - breaking .73, let's see .75 today.
TELK +8.76%
CGR-double bottom, 1.32 better hold.
NEWN-added more .80
ANX looks ready
LOL...give it to her IAL
Yes...give her some. she's so ready to wake up.
NEWN-yep...added some .78s
just added some NEWN, looks ready for bouncey